We invite you to explore the links below to find out more about commercial litigation, intellectual property, mesothelioma cancer, pharmaceutical (drug) liability, product liability, toxic exposures and wrongful death!
|
Syndicate
FDA: Press Releases
Press releases from FDA
Updated: 1 hour 53 min ago
FDA and industry reach agreement in principle on medical device user fees
The FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would authorize the FDA to collect $595 million in user fees over five years, plus adjustments for inflation. Details of the agreement, such as the fee structure, are expected to be finalized soon.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancer
The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today’s action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA approves Kalydeco to treat rare form of cystic fibrosis
The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA takes action against New York cheese manufacturer
The U.S. Food and Drug Administration is asking a federal court to prevent a New York cheese manufacturer from operating because of a history of unsanitary conditions and producing cheese in a facility contaminated with Listeria monocytogenes bacteria.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA approves new treatment for most common type of skin cancer
Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic).
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA approves Inlyta to treat patients with a type of advanced kidney cancer
The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
Department of Justice files Consent Decree of Permanent injunction against Ranbaxy
Generic drug manufacturer agrees to remedy deviations from the current good manufacturing practice requirements and to correct data integrity problems at numerous facilities
Categories: NEWS: U.S. Food and Drug Administration (FDA)
Maine company holds cold smoked salmon product after FDA order
A Maine food processing and storage company destroyed its cold smoked salmon product under the supervision of the U.S. Food and Drug Administration after inspectors found Listeria monocytogenes within the firm’s facility and on processing equipment
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri
Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn’s disease (CD).
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA approves Voraxaze to treat patients with toxic methotrexate levels
The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure.
Methotrexate is a commonly used cancer chemotherapy drug normally eliminated from the body by the kidneys. However, patients receiving high doses of methotrexate may develop kidney failure.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA expands use of endovascular graft to treat aortic tears
The U.S. Food and Drug Administration today expanded the approved usage for an endovascular graft manufactured by W.L. Gore and Associates Inc. to include treatment of life-threatening tears or ruptures of the aorta (thoracic aortic transection). (MB)
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA completes work on three drug user fee programs
The U.S. Food and Drug Administration has completed its recommendations for three user fee programs that will help speed safe and effective drugs and lower-cost generic drug and biosimilar biological products to patients, FDA Commissioner Margaret A. Hamburg, M.D. said today. The recommendations were transmitted to Congress today by Health and Human Services Secretary Kathleen Sebelius.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA to protect important class of antimicrobial drugs for treating human illness
The U.S. Food and Drug Administration today issued an order that prohibits certain uses of the cephalosporin class of antimicrobial drugs in cattle, swine, chickens and turkeys effective April 5, 2012.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA expands use of Prevnar 13 vaccine for people ages 50 and older
Prevnar 13, a pneumococcal 13-valent conjugate vaccine, was approved today by the U.S. Food and Drug Administration for people ages 50 years and older to prevent pneumonia and invasive disease caused by the bacterium, Streptococcus pneumoniae.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA to approve shared system REMS for TIRF products
The U.S. Food and Drug Administration today approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for the transmucosal immediate-release fentanyl (TIRF) products.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA: Chicago-area sandwich manufacturer agrees to stop production
The U.S. Food and Drug Administration announced today that a Chicago-area company has agreed to stop making its ready-to-eat sandwiches and produce after FDA investigators repeatedly found unsanitary conditions and bacterial contamination in the facility.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA expands use of HIV drug Isentress to children and adolescents
Isentress (raltegravir) was approved today by the U.S. Food and Drug Administration for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents ages 2-18.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA: Do not use ShoulderFlex Massager
The U.S. Food and Drug Administration is warning consumers again not to use the ShoulderFlex Massager, imported by King International and sold by various companies, due to serious potential health risks.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA collaboration to monitor rare eye condition associated with cataract surgery
The U.S. Food and Drug Administration and other government and professional organizations today unveiled a program to monitor medical devices used in cataract surgery in an effort to stem outbreaks of a rare, inflammatory condition associated with the procedure.
Categories: NEWS: U.S. Food and Drug Administration (FDA)
FDA approves mechanical cardiac assist device for children with heart failure
The U.S. Food and Drug Administration today approved a medical device that supports the weakened heart of children with heart failure to help keep them alive until a donor for a heart transplant can be found.
The mechanical pulsatile cardiac assist device is called the EXCOR Pediatric System, made by a German company, Berlin Heart. The device comes in graduated sizes to fit children from newborns to teens.
Categories: NEWS: U.S. Food and Drug Administration (FDA)